Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
UTHR [NASD]
United Therapeutics Corporation
Index- P/E25.95 EPS (ttm)5.10 Insider Own0.10% Shs Outstand47.27M Perf Week6.17%
Market Cap6.26B Forward P/E13.33 EPS next Y9.93 Insider Trans-3.28% Shs Float46.67M Perf Month-1.96%
Income281.70M PEG2.18 EPS next Q1.97 Inst Own96.90% Short Float11.46% Perf Quarter45.69%
Sales1.20B P/S5.20 EPS this Y-42.60% Inst Trans0.19% Short Ratio5.71 Perf Half Y48.71%
Book/sh25.48 P/B5.19 EPS next Y16.82% ROA13.90% Target Price117.64 Perf Year58.55%
Cash/sh12.01 P/C11.02 EPS next 5Y11.90% ROE21.70% 52W Range81.60 - 136.93 Perf YTD17.05%
Dividend- P/FCF25.48 EPS past 5Y38.20% ROI11.80% 52W High-3.34% Beta1.32
Dividend %- Quick Ratio1.20 Sales past 5Y31.70% Gross Margin88.50% 52W Low62.20% ATR4.72
Employees706 Current Ratio1.30 Sales Q/Q15.00% Oper. Margin38.90% RSI (14)66.51 Volatility3.19% 3.83%
OptionableYes Debt/Eq0.30 EPS Q/Q38.20% Profit Margin23.40% Rel Volume0.49 Prev Close128.78
ShortableYes LT Debt/Eq0.00 EarningsOct 27 BMO Payout0.00% Avg Volume936.70K Price132.35
Recom2.40 SMA203.38% SMA5011.50% SMA20029.10% Volume460,070 Change2.78%
15-Oct-14Upgrade Standpoint Research Hold → Buy $144
29-Aug-14Reiterated Standpoint Research Buy $118 → $140
30-Jul-14Reiterated H.C. Wainwright Buy $120 → $150
07-Apr-14Upgrade Standpoint Research Hold → Buy $118
26-Feb-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
26-Feb-14Reiterated Ladenburg Thalmann Buy $138 → $135
31-Dec-13Reiterated Argus Buy $120 → $130
23-Dec-13Upgrade Ladenburg Thalmann Neutral → Buy $138
02-Dec-13Reiterated Argus Buy $85 → $110
05-Aug-13Reiterated Argus Buy $75 → $85
30-Jul-13Downgrade Standpoint Research Buy → Hold
20-Jun-13Upgrade Standpoint Research Hold → Buy
15-May-13Downgrade Standpoint Research Buy → Hold
25-Mar-13Reiterated Ladenburg Thalmann Buy $69 → $63
27-Feb-13Reiterated RBC Capital Mkts Sector Perform $45 → $50
03-Aug-12Downgrade Standpoint Research Buy → Hold
27-Apr-12Downgrade Canaccord Genuity Buy → Hold
26-Mar-12Initiated Canaccord Genuity Buy $56
12-Mar-12Initiated Standpoint Research Buy $65
14-Feb-12Reiterated Brean Murray Buy $55 → $57
22-Oct-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
21-Oct-14 06:00AM  United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014 PR Newswire
15-Oct-14 01:27PM  United Therapeutics upgraded by Standpoint Research Briefing.com
14-Oct-14 05:05PM  Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Zacks
10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
26-Sep-14 03:07PM  Biotech's future: The Government is key Yahoo Finance
25-Sep-14 12:34PM  Artificial intelligence doppelgangers and life in outer space closer than you think Yahoo Finance
08:38AM  Highest-paid female CEO used to be a man Yahoo Finance
24-Sep-14 09:36AM  Can the Uptrend Continue for United Therapeutics (UTHR)? Zacks
23-Sep-14 05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
08:10AM  Moving Average Crossover Alert: United Therapeutics (UTHR) Zacks
22-Sep-14 05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
17-Sep-14 07:30AM  Axsome Therapeutics Announces Appointments to Its Board of Directors GlobeNewswire
16-Sep-14 03:00AM  Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market GlobeNewswire
15-Sep-14 05:32PM  Today's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
11:19AM  Hedge fund offers $1 million to cure...aging? at CNBC
10-Sep-14 04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
09-Sep-14 03:50PM  Pluristem & United Therapeutics Progress with Phase I Study Zacks
03-Sep-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
02-Sep-14 05:25PM  United Therapeutics Soars on Remodulin Patent Case Win Zacks
07:58AM  United Therapeutics (UTHR) Shares March Higher, Can It Continue? Zacks
29-Aug-14 04:21PM  United Therapeutics Legal Victory Sends Stock Flying at Investor's Business Daily +28.51%
02:21PM  United Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' at Barrons.com
02:02PM  United Therapeutics rises on drug-patent ruling AP
12:49PM  District Court Decision Received In Remodulin Patent Case PR Newswire
26-Aug-14 07:50AM  Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% Zacks
25-Aug-14 11:05AM  Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals StockTwits
22-Aug-14 04:40PM  OncoGenex's Custirsen Passes First Interim Futility Analysis Zacks
08:25AM  Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Zacks
21-Aug-14 08:56AM  Gilead (GILD) Hits 52-Week High Thanks to Sovaldi Zacks
20-Aug-14 05:21PM  Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Zacks
08:40AM  Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher Zacks
06:51AM  Can United Therapeutics (UTHR) Keep the Earnings Streak Alive This Quarter? Zacks
14-Aug-14 02:30PM  Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Zacks
02-Aug-14 01:04PM  UNITED THERAPEUTICS CORP Financials EDGAR Online Financials
31-Jul-14 12:20PM  United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Zacks
30-Jul-14 10:56AM  Perilous Reversal Watch: United Therapeutics (UTHR) at TheStreet -5.01%
07:08AM  United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Zacks
29-Jul-14 07:07AM  Q2 2014 United Therapeutics Earnings Release - Before Market Open CCBN +8.10%
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Second Quarter 2014 Financial Results PR Newswire
22-Jul-14 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014 PR Newswire
10-Jul-14 03:43PM  Supernus Up on Non-Dilutive Royalty Deal Zacks
09-Jul-14 05:00PM  Pluristem Initiates Trial in South Korea Zacks
08-Jul-14 07:30AM  Supernus to Receive $30 Million in Non-Dilutive Royalty Deal GlobeNewswire
05:47AM  United Therapeutics draws bulls optionMONSTER
27-Jun-14 09:14AM  Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals at Motley Fool
06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc EDGAR Online
06:00AM  United Therapeutics Announces Additional $500 Million Share Repurchase Program PR Newswire
19-Jun-14 01:18PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty Business Wire
16-Jun-14 09:49AM  United Therapeutics (UTHR) Marked As A Dead Cat Bounce Stock at TheStreet
07:26AM  Weakness Seen in United Therapeutics (UTHR): Stock Tumbles 8.0% Zacks
13-Jun-14 04:46PM  Can Pig Lungs Keep Growth Flying for United Therapeutics Shareholders? at Motley Fool -7.97%
09-Jun-14 02:34PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty PR Newswire
21-May-14 05:34PM  [video] Momentum trades alive: ARCB, UTHR at CNBC
20-May-14 05:00PM  Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM) GlobeNewswire
11:19AM  Why I'm Long Supernus, A Small Specialty Pharma Company at Seeking Alpha
13-May-14 11:12AM  3 picks for bent but not broken biotech Breakout
11-May-14 05:45AM  Industry Ranks May 2014 at Seeking Alpha
08-May-14 12:16PM  Insider Trading Alert - K, EQR And UTHR Traded By Insiders at TheStreet
06-May-14 06:07AM  Pig organ transplants to humans move a step closer at Financial Times
06:00AM  Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc., a Subsidiary of United Therapeutics Corporation, to Develop Humanized Pig Organs to Revolutionize Transplantation Field PR Newswire
06:00AM  Genome scientist Craig Venter in deal to make humanized pig organs Reuters
05-May-14 06:32PM  3 Biotech Stocks Making Big Moves Last Week at Motley Fool
01-May-14 12:10PM  United Therapeutics Gains on Q1 Earnings Zacks
29-Apr-14 06:00PM  United Therapeutics Management Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha +6.13%
07:07AM  Q1 2014 United Therapeutics Earnings Release - Before Market Open CCBN
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports First Quarter 2014 Financial Results PR Newswire
22-Apr-14 06:00AM  United Therapeutics Corporation To Announce First Quarter 2014 Financial Results Before Market Open On Tuesday, April 29, 2014 PR Newswire
01-Apr-14 04:03AM  United Therapeutics: 7 Different Insiders Have Sold Shares This Month at Seeking Alpha
26-Mar-14 05:33PM  [video] The false temptation of growth at CNBC
09:13AM  Todays Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam at Motley Fool
06:00AM  Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin PR Newswire
18-Mar-14 04:31PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
16-Mar-14 05:16PM  Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook at Seeking Alpha
11-Mar-14 01:56PM  United Therapeutics retreats after FDA denies petition on Remodulin label at theflyonthewall.com
12:52PM  United Therapeutics: A Profitable Biotech With A Potentially Undervalued Pipeline at Seeking Alpha
12:24PM  United Therapeutics lower after FDA denies Remodulin citizen petition at theflyonthewall.com
27-Feb-14 08:10AM  United Therapeutics Slips on Q4 Earnings Report Zacks
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE ACEOOct 23Option Exercise32.379,662312,7855,687Oct 23 09:26 PM
MAHON PAUL AEVP & General CounselOct 23Option Exercise30.755,000153,75039,832Oct 23 08:49 PM
ROTHBLATT MARTINE ACEOOct 23Sale130.209,6621,258,037140Oct 23 09:26 PM
MAHON PAUL AEVP & General CounselOct 23Sale130.235,000651,16434,832Oct 23 08:49 PM
ROTHBLATT MARTINE ACEOOct 22Option Exercise63.222,211139,7792,351Oct 23 09:26 PM
ROTHBLATT MARTINE ACEOOct 22Sale128.932,211285,073140Oct 23 09:26 PM
ROTHBLATT MARTINE ACEOOct 20Option Exercise52.652,592136,4692,732Oct 21 05:46 PM
ROTHBLATT MARTINE ACEOOct 20Sale124.832,592323,568140Oct 21 05:46 PM
JEFFS ROGERPresident & COOOct 17Option Exercise30.7510,000307,50011,234Oct 17 09:25 PM
JEFFS ROGERPresident & COOOct 17Sale124.8510,0001,248,4781,234Oct 17 09:25 PM
MAHON PAUL AEVP & General CounselOct 16Option Exercise33.146,000198,84040,832Oct 23 08:49 PM
ROTHBLATT MARTINE ACEOOct 16Option Exercise32.379,662312,7855,687Oct 17 09:08 PM
Ferrari John MaximCFOOct 16Option Exercise50.0910,000500,90010,407Oct 17 09:14 PM
MAHON PAUL AEVP & General CounselOct 16Sale124.386,000746,28034,832Oct 23 08:49 PM
ROTHBLATT MARTINE ACEOOct 16Sale122.209,6621,180,738140Oct 17 09:08 PM
Ferrari John MaximCFOOct 16Sale124.3810,0001,243,800407Oct 17 09:14 PM
ROTHBLATT MARTINE ACEOOct 15Option Exercise63.222,211139,7792,351Oct 16 08:36 PM
ROTHBLATT MARTINE ACEOOct 15Sale120.082,211265,497140Oct 16 08:36 PM
ROTHBLATT MARTINE ACEOOct 13Option Exercise52.652,592136,4692,732Oct 14 08:41 AM
ROTHBLATT MARTINE ACEOOct 13Sale124.312,592322,221140Oct 14 08:41 AM
ROTHBLATT MARTINE ACEOOct 09Option Exercise32.379,662312,7855,687Oct 09 09:02 PM
ROTHBLATT MARTINE ACEOOct 09Sale129.979,6621,255,757140Oct 09 09:02 PM
ROTHBLATT MARTINE ACEOOct 08Option Exercise63.222,211139,7792,351Oct 09 04:43 PM
ROTHBLATT MARTINE ACEOOct 08Sale131.502,211290,757140Oct 09 04:43 PM
JEFFS ROGERPresident & COOOct 07Option Exercise33.1435,0001,159,90036,234Oct 07 08:11 PM
JEFFS ROGERPresident & COOOct 07Sale130.1435,0004,554,9001,234Oct 07 08:11 PM
ROTHBLATT MARTINE ACEOOct 06Option Exercise52.652,592136,4692,732Oct 07 04:56 PM
ROTHBLATT MARTINE ACEOOct 06Sale129.322,592335,195140Oct 07 04:56 PM
JEFFS ROGERPresident & COOOct 03Option Exercise30.7510,000307,50011,234Oct 07 07:23 AM
JEFFS ROGERPresident & COOOct 03Sale129.7910,0001,297,9171,234Oct 07 07:23 AM
MAHON PAUL AEVP & General CounselOct 02Option Exercise33.146,000198,84040,832Oct 02 08:16 PM
Ferrari John MaximCFOOct 02Option Exercise50.0910,000500,90010,407Oct 02 08:21 PM
DWEK RAYMONDDirectorOct 02Option Exercise30.753,00092,2503,000Oct 02 08:34 PM
ROTHBLATT MARTINE ACEOOct 02Option Exercise32.379,662312,7855,687Oct 02 08:45 PM
DWEK RAYMONDDirectorOct 02Sale131.103,000393,2920Oct 02 08:34 PM
ROTHBLATT MARTINE ACEOOct 02Sale127.729,6621,234,049140Oct 02 08:45 PM
Ferrari John MaximCFOOct 02Sale129.4610,0001,294,600407Oct 02 08:21 PM
MAHON PAUL AEVP & General CounselOct 02Sale129.466,000776,76034,832Oct 02 08:16 PM
ROTHBLATT MARTINE ACEOOct 01Option Exercise63.222,211139,7792,351Oct 02 05:53 PM
ROTHBLATT MARTINE ACEOOct 01Sale127.402,211281,682140Oct 02 05:53 PM
JEFFS ROGERPresident & COOSep 30Option Exercise33.1420,000662,80021,234Oct 02 04:14 PM
JEFFS ROGERPresident & COOSep 30Sale128.6520,0002,573,0001,234Oct 02 04:14 PM
Giltner RichardDirectorSep 25Option Exercise31.0420,000620,70020,000Sep 26 04:23 PM
MAHON PAUL AEVP & General CounselSep 25Option Exercise30.755,000153,75039,832Sep 26 04:23 PM
ROTHBLATT MARTINE ACEOSep 25Option Exercise34.564,115142,2144,255Sep 26 04:25 PM
ROTHBLATT MARTINE ACEOSep 25Option Exercise30.755,547170,5705,687Sep 26 04:24 PM
Giltner RichardDirectorSep 25Sale134.9420,0002,698,7790Sep 26 04:23 PM
MAHON PAUL AEVP & General CounselSep 25Sale133.775,000668,85534,832Sep 26 04:23 PM
ROTHBLATT MARTINE ACEOSep 25Sale133.184,115548,024140Sep 26 04:25 PM
ROTHBLATT MARTINE ACEOSep 25Sale134.265,547744,723140Sep 26 04:24 PM
JEFFS ROGERPresident & COOSep 23Option Exercise33.1450,0001,657,00051,234Sep 24 04:21 PM
JEFFS ROGERPresident & COOSep 23Sale131.0250,0006,551,0001,234Sep 24 04:21 PM
JEFFS ROGERPresident & COOSep 19Option Exercise30.7510,000307,50011,234Sep 19 08:19 PM
JEFFS ROGERPresident & COOSep 19Sale129.6010,0001,296,0001,234Sep 19 08:19 PM
MAHON PAUL AEVP & General CounselSep 18Option Exercise33.146,000198,84040,832Sep 22 01:19 PM
ROTHBLATT MARTINE ACEOSep 18Option Exercise32.379,662312,7855,687Sep 18 09:06 PM
Ferrari John MaximCFOSep 18Option Exercise50.0910,000500,90010,407Sep 18 09:10 PM
MAHON PAUL AEVP & General CounselSep 18Sale130.936,000785,58034,832Sep 22 01:19 PM
ROTHBLATT MARTINE ACEOSep 18Sale127.359,6621,230,409140Sep 18 09:06 PM
Ferrari John MaximCFOSep 18Sale130.9310,0001,309,300407Sep 18 09:10 PM
JEFFS ROGERPresident & COOSep 17Option Exercise33.1420,000662,80021,234Sep 18 08:55 PM
JEFFS ROGERPresident & COOSep 17Sale127.0120,0002,540,2001,234Sep 18 08:55 PM
ROTHBLATT MARTINE ACEOSep 15Option Exercise52.6450,0002,632,00050,140Sep 16 05:27 PM
ROTHBLATT MARTINE ACEOSep 15Sale124.5250,0006,226,144140Sep 16 05:27 PM
MAHON PAUL AEVP & General CounselSep 11Option Exercise30.755,000153,75039,832Sep 12 06:34 PM
ROTHBLATT MARTINE ACEOSep 11Option Exercise32.379,662312,7855,687Sep 12 06:35 PM
MAHON PAUL AEVP & General CounselSep 11Sale120.705,000603,49134,832Sep 12 06:34 PM
ROTHBLATT MARTINE ACEOSep 11Sale120.799,6621,167,037140Sep 12 06:35 PM
Giltner RichardDirectorSep 10Option Exercise31.0420,000620,70020,000Sep 11 05:06 PM
ROTHBLATT MARTINE ACEOSep 10Option Exercise63.2250,0003,161,00050,140Sep 11 05:10 PM
Giltner RichardDirectorSep 10Sale119.9520,0002,399,0990Sep 11 05:06 PM
ROTHBLATT MARTINE ACEOSep 10Sale120.0150,0006,000,350140Sep 11 05:10 PM
JEFFS ROGERPresident & COOSep 09Option Exercise32.4820,676671,63716,234Sep 09 08:34 PM
JEFFS ROGERPresident & COOSep 09Sale117.1820,6762,422,8631,234Sep 09 08:34 PM
JEFFS ROGERPresident & COOSep 05Option Exercise30.7510,000307,50011,234Sep 05 06:08 PM
JEFFS ROGERPresident & COOSep 05Sale111.2910,0001,112,9391,234Sep 05 06:08 PM
CAUSEY CHRISTOPHERDirectorSep 04Option Exercise41.141,50061,7102,233Sep 05 05:51 PM
ROTHBLATT MARTINE ACEOSep 04Option Exercise32.379,662312,7855,687Sep 05 05:59 PM
Ferrari John MaximCFOSep 04Option Exercise50.0910,000500,90010,407Sep 05 05:19 PM
DWEK RAYMONDDirectorSep 04Option Exercise30.753,00092,2503,000Sep 05 05:39 PM
CAUSEY CHRISTOPHERDirectorSep 04Sale113.331,500169,989733Sep 05 05:51 PM
ROTHBLATT MARTINE ACEOSep 04Sale112.879,6621,090,524140Sep 05 05:59 PM
Ferrari John MaximCFOSep 04Sale112.3810,0001,123,800407Sep 05 05:19 PM
DWEK RAYMONDDirectorSep 04Sale113.403,000340,2060Sep 05 05:39 PM
MAHON PAUL AEVP & General CounselAug 28Option Exercise30.755,000153,75039,832Aug 29 06:32 PM
ROTHBLATT MARTINE ACEOAug 28Option Exercise32.997,014231,3594,255Aug 29 04:06 PM
MAHON PAUL AEVP & General CounselAug 28Sale92.075,000460,34034,832Aug 29 06:32 PM
ROTHBLATT MARTINE ACEOAug 28Sale92.467,014648,510140Aug 29 04:06 PM
Ferrari John MaximCFOAug 21Option Exercise50.0910,000500,90010,407Aug 22 04:07 PM
ROTHBLATT MARTINE ACEOAug 21Option Exercise32.389,640312,1085,665Aug 22 04:09 PM
Ferrari John MaximCFOAug 21Sale93.7510,000937,500407Aug 22 04:07 PM
ROTHBLATT MARTINE ACEOAug 21Sale93.139,640897,770140Aug 22 04:09 PM
ROTHBLATT MARTINE ACEOAug 14Option Exercise34.564,115142,2144,255Aug 15 04:42 PM
MAHON PAUL AEVP & General CounselAug 14Option Exercise30.7510,000307,50044,832Aug 15 04:44 PM
ROTHBLATT MARTINE ACEOAug 14Sale88.394,115363,728140Aug 15 04:42 PM
MAHON PAUL AEVP & General CounselAug 14Sale88.4110,000884,06834,832Aug 15 04:44 PM
Ferrari John MaximCFOAug 07Option Exercise50.0910,000500,90010,407Aug 11 08:15 AM
ROTHBLATT MARTINE ACEOAug 07Option Exercise34.564,115142,2144,255Aug 11 08:16 AM
Ferrari John MaximCFOAug 07Sale86.4410,000864,400407Aug 11 08:15 AM
ROTHBLATT MARTINE ACEOAug 07Sale88.404,115363,747140Aug 11 08:16 AM